Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

August 20, 2025

Company name: TAUNS Laboratories, Inc.
Representative: Masaki Nonaka, President and CEO
(Code no.: 197A, Standard Market, Tokyo Stock Exchange)
Contact person: Yoshio Uchiyama, Director and CFO
Tel: +81-55-957-3090

Notice Regarding Formulation of Mid-Term Management Plan

We are pleased to announce that we have formulated a mid-term management plan covering the period from June 2026 to June 2030.

For details, please refer to the attached document.

Mid-Term Management Plan

FY 2026/6 – FY 2030/6

TAUNS Laboratories, Inc.

August 20, 2025

INDEX

Vision for Mid-term Management Plan

- **Medical technology is becoming increasingly sophisticated in response to social issues such as the need for next pandemic countermeasures and the growing demand for preventive and personalized medicine due to an aging population and rising social security costs. TAUNS aims to solve social issues using diagnostic technology and data.**

Corporate slogan: "Peace of mind through diagnostic technology."

Vision for the Mid-Term Management Plan: Solving social issues with diagnostic technology and data

- The introduction of new diagnostic technologies will allow us to address new medical needs, such as next pandemic countermeasures, preventive medicine, and personalized medicine.
- By combining our long-established diagnostic technologies with cutting-edge medical data analysis utilizing mathematical models and AI, we will build a new medical technology platform to address increasingly complex social issues.

Acceleration of aging society



Increase in social security expenses

Increase of over 20% in 10 years



Advances in medical technology

Effective treatments through technological innovation

- Genomic medicine
- AI-driven drug discovery
- Immunotherapy

Increased demand for self-care

- Reduction in medical facilities due to reorganization
- Promoting self-care as a policy measure to curb medical expenses and address labor shortages.
- Emergence of needs for measures at the preventive and pre-disease stages.

Business Domain

- **In addition to antigen testing, new technologies, such as digital immunoassays (D-IA), will be introduced to expand the range of diseases and stages for which point-of-care testing (POCT) can be used.**
- **We are entering the chronic disease field by introducing new testing technologies through collaboration with alliance companies.**

		Before onset		After onset of disease		Before treatment	After treatment
		Prevention/Pre-disease	Screening	Definitive diagnosis	Companion diagnosis		Monitoring
Infectious disease	Respiratory infections		Antigen testing/ nodoca	D-IA			
	Sexually transmitted diseases	Microbiome	D-IA	D-IA			
	Other	Microbiome	Antigen testing/D-IA	D-IA			Immune Profile
Chronic disease	Cancer	Genome/ Microbiome	MicroRNA/ nodoca	MicroRNA	Immune profile		MicroRNA/ Immune profile
	Dementia	Genome/ Microbiome	MicroRNA/D-IA	MicroRNA/D-IA			MicroRNA/D-IA
	Other	Genome/ Microbiome	MicroRNA/D-IA	D-IA	Immune profile		Microbiome/ MicroRNA

At a glance

	Recent performance Fiscal year ended June 2025		Mid-term plan target Fiscal year ending June 2030
Sales	18.62 billion yen	▶	30.07 billion yen
Operating Income	8.26 billion yen	▶	12.98 billion yen
EBITDA	8.98 billion yen	▶	14.81 billion yen
Operating Income Margin	44.4%	▶	43.2%
Net Income	6.31 billion yen	▶	8.96 billion yen
ROE	40.7%	▶	Over 25%*

*A level that comprehensively takes into consideration shareholder returns and increases in shareholders' equity during the mid-term management plan period.

Key measures for achieving our vision

01

Evolution and expansion of POCT

Introduction of new products and technologies with high competitive advantage

02



Introduction of new diagnostic technologies

Entry into the chronic disease field through cooperation with capital partners

03

Establishment of a data utilization infrastructure

Establishment of an integrated data utilization platform based on a biobank linked to PHR/EHR

04

Strengthening of management base

Establishing the necessary framework to implement key measures

Key measures for achieving our vision

01

Evolution and expansion of POCT

Introduction of new products and technologies with high competitive advantage

02



Introduction of new diagnostic technologies

Entry into the chronic disease field through cooperation with capital partners

03

Establishment of a data utilization infrastructure

Establishment of an integrated data utilization platform based on a biobank linked to PHR/EHR

04

Strengthening of management base

Establishing the necessary framework to implement key measures

Measure 1: Evolution and Expansion of POCT

- **In addition to expanding antigen testing, we will introduce new technologies such as D-IA and nodoca to lead the way in the advancement and diversification of POCT.**

Background of POCT Evolution and Expansion

- Antigen testing is evaluated for its simplicity, speed, low cost, and reasonably accurate, making it the mainstream technology in current POCT
- In some cases, such as tests for certain respiratory infections or sexually transmitted infections, antigen testing may be insufficient in terms of accuracy or the number of simultaneous tests that can be performed
- During outbreaks of respiratory infections, there may be cases where testing kits are in short supply or long testing times constrain the operations of medical institutions

TAUNS' POCT Strategy

- Improving the accuracy of antigen testing, expanding the range of test items, and enhancing combo test products
- D-IA achieves highly accurate multi-panel testing with the same simplicity, speed, and low cost as antigen testing. This enables affordable and comprehensive definitive diagnosis of various infectious diseases.
- The introduction of nodoca, an AI-based image diagnosis system, enables testing in just a few tens of seconds without requiring patients to provide samples. This also resolves supply concerns for testing kits.

POCT Technology Correlation Diagram



While focusing on antigen testing, we pursue both the evolution of test accuracy (D-IA) and usability and low cost (nodoca)

Measure 1: Evolution and Expansion of POCT

- **By building a wide range of POCT testing platforms, we can respond appropriately to diverse testing needs.**

Technology	Overview	Applicable Business Domains	Key measures during the medium-term plan period
nodoca 	• AI for pharyngeal image analysis using a dedicated camera • Non-invasive test with minimal patient burden and short testing time of a few seconds to a few tens of seconds • By expanding the dataset, simultaneous testing of multiple parameters is possible with a single image capture	Respiratory infection screening	• Improved accuracy and expanded test items through joint research with Aillis, Inc. • Cross-selling of antigen tests with nodoca and expansion of TAUNS' customer base through nodoca
Antigen testing 	• Currently the mainstream POCT method. No dedicated equipment required; visual inspection is performed. • Highly versatile and applicable to a wide range of items • Simple, rapid, and low-cost	Respiratory infection screening Other infectious disease screening	• Improved accuracy and development efficiency through introduction of new technologies such as antibody development AI • Expansion of combo kit lineup • Expansion into new items beyond respiratory infections
D-IA 	• TAUNS' next-generation POCT • Achieves high-precision testing comparable to PCR, with the same simplicity, speed, and low cost as antigen testing • Consideration of low-invasive samples such as saliva • Flexible test configuration options, such as 5 items × 4 samples, 10 items × 2 samples, and 20 items × 1 sample	Respiratory infection definitive diagnosis Sexually transmitted Infection screening and definitive diagnosis Other infectious disease screening and definitive diagnosis Dementia screening and monitoring	• Further precision improvement, cost reduction, and expansion of simultaneous measurement items through joint research with ZACROS Corporation • Launch of "Respiratory Infectious Disease Multi-Panel Definitive Diagnosis" during the medium-term plan period

Key measures for achieving our vision

01

Evolution and expansion of POCT

Introduction of new products and technologies with high competitive advantage

02



Introduction of new diagnostic technologies

Entry into the chronic disease field through cooperation with capital partners

03

Establishment of a data utilization infrastructure

Establishment of an integrated data utilization platform based on a biobank linked to PHR/EHR

04

Strengthening of management base

Establishing the necessary framework to implement key measures

Measure 2: Introduction of New Diagnostic Technologies

- **Through collaboration with TAUNS Clinical Lab (clinical testing center) and its capital partner, we will implement multi-omics testing services such as genomics, epigenomics, immune profiling, and microbiome analysis..**



GENEX	CRAIF	ImmuniT Research Inc.	KINS
Cancer prevention and pre-disease Dementia prevention and pre-disease Other chronic disease prevention and pre-disease	Cancer screening and definitive diagnosis Dementia screening and definitive diagnosis Other chronic disease screening and definitive diagnosis	Cancer companion diagnostics and monitoring Other chronic disease companion ciagnosis and other infectious disease monitoring	Prevention and pre-disease of various diseases Other chronic disease monitoring

Measure 2: Introduction of New Diagnostic Technologies

- **In collaboration with capital partners possessing advanced and distinctive technologies, introduce new diagnostic technologies and enter the chronic disease field.**
- **Aim to implement a new service that integrates “testing + intervention” for immune profiles and the microbiome.**

	Overview	Key measures during the medium-term plan period
Genome	• Analyze genetic disease risk using genome analysis • Combining various test data with genome analysis to provide highly accurate disease risk prediction	• Clinical research on the association between chronic diseases and genomic variants (SNPs) using genome-wide association studies (GWAS) (joint research with universities) • Comparative research on WGS/WES analysis of disease-associated genes and various sample test results (same as above)
Micro RNA	• Using proprietary small RNA sequencing technology to comprehensively analyze urinary microRNA and construct disease prediction models using machine learning algorithms • By detecting microRNA in urine, achieve non-invasive and highly accurate cancer screening. Consideration for application to other diseases such as dementia	• Expansion of cancer microRNA testing for medical institutions • Launch of "Dementia MicroRNA Testing" as an LDT during the medium-term plan period
Immune Profile	• A technology that analyzes immune cell clusters in whole blood samples from patients to perform high-precision, simple pre-evaluation of the efficacy of immune checkpoint inhibitors • Applications for companion diagnostics and monitoring of autoimmune diseases and other chronic conditions are also under consideration	• Clinical research on drug administration decisions and treatment efficacy prediction for immune checkpoint inhibitors in lung cancer (joint research with a cancer core hospital) • Launch "cancer companion diagnostics" as an LDT during the mid-term plan period, consider integrated use with new cancer cell therapies
Micro Biome	• Analyzing the relationship between the microbiome (microbial community) and various diseases to establish indicators for appropriate interventions	• Launch of a DTC microbiome testing service for supplement purchasers • Joint development of new services combining microbiome testing for medical institutions and doctor-recommended supplements

Key measures for achieving our vision

01

Evolution and expansion of POCT

Introduction of new products and technologies with high competitive advantage

02



Introduction of new diagnostic technologies

Entry into the chronic disease field through cooperation with capital partners

03

Establishment of a data utilization infrastructure

Establishment of an integrated data utilization platform based on a biobank linked to PHR/EHR

04

Strengthening of management base

Establishing the necessary framework to implement key measures

Measure 3: Establishment of a Data Utilization Infrastructure

- **Through health checkups, comprehensive medical examinations, and other means, collect and accumulate (biobank) stored samples linked to medical data such as EHR and PHR over time, and build an integrated data utilization platform that combines sample data and various medical data.**

TAUNS Initiatives

- In collaboration with university medical schools, medical associations, health screening and comprehensive health checkup providers, etc., we will collect and accumulate samples from health screening and comprehensive health checkup participants for research purposes with their consent (Dynamic opt-in).
- By collaborating with EHR/PHR service providers, we aim to link stored samples with various medical data with the consent of the patients. (Linkable anonymization)
- Aim to continuously collect tens of thousands of stored samples linked to various medical data over a long period of time.
- Through large-scale expansion, we will cover diverse age groups, demographics, and disease states, and through long-term continuous collection, we will be able to track temporal changes.

Image of Integrated Data Utilization Infrastructure



Measure 3: Establishment of a Data Utilization Infrastructure

- **Research using biobank samples linked to medical data to explore new biomarkers for early diagnosis.**
- **Using an integrated data utilization platform, we aim to develop software medical devices (SaMD) that analyze disease mechanisms using mathematical models and AI, and perform disease screening, prediction of disease progression, and recommendation of appropriate interventions.**

Research and Development using an Integrated Data Utilization Infrastructure







Development of software medical devices



Key measures for achieving our vision

01

Evolution and expansion of POCT

Introduction of new products and technologies with high competitive advantage

02



Introduction of new diagnostic technologies

Entry into the chronic disease field through cooperation with capital partners

03

Establishment of a data utilization infrastructure

Establishment of an integrated data utilization platform based on a biobank linked to PHR/EHR

04

Strengthening of management base

Establishing the necessary framework to implement key measures

Measure 4: Strengthening of Management Base



Business Alliances

Strengthen our position in domestic and overseas markets

Strategic Investment

Expansion of capabilities and introduction of new technologies

Human Capital Investment

Build a culture that contributes to sustainable growth

Measure 4: Strengthening of Management Base



Measure 4-1:Business Alliance - Domestic Market

- **Solidify our position in domestic market through partnerships with major operators**
- **Initiate discussions with potential partners to enter the OTC market, which has not been targeted to date**

Business alliance targeting clinics and hospitals in Japan

	SHIONOGI	Roche
Sales target	Clinics	Hospitals
Medical Dept.	General internal medicine, etc.	-
Distributon	Co-promotion	Co-marketing
Sales strategy	Increase the number of newly adopting facilities and expand market share through information providing activities to general practitioners by Shionogi's MRs.	Increase the number of newly adopting facilities and expand market share through information providing activities to medical institutions, mainly large hospitals by Roche Diagnostics' MRs.

Each company's area of expertise



Combining each company's strengths to comprehensively approach the entire market

Measure 4-1:Business Alliance - Overseas Market

- **In addition to strengthening ties with existing distributors and capital partners, we will expand into new areas to enhance our presence in overseas markets.**
- **Currently, transactions are mainly with agents and partners in each country, but discussions are underway to form new partnerships with global partners.**

Strategies during the mid-term plan period

- Strengthen partnerships with existing distributors in Asia and Europe

Currently contracted with 27 distributors mainly in Asia and EU

*As of May 2025

- Market development in Africa

Market development in collaboration with Medlynks By Connect Afya Medical Centre Limited, a capital partner in Kenya.

- Initiate research to enter the North American market
- Prepare for overseas expansion centered on new products such as D-IA
- Strengthen collaboration with UNOPS and response to tenders from various countries
- Negotiate partnerships with potential global partners

Existing sales regions and regions planned for expansion

Measure 4: Strengthening of Management Base



Business Alliances

Strengthen our position in domestic and overseas markets

Strategic Investment

Expansion of capabilities and introduction of new technologies

Human Capital Investment

Build a culture that contributes to sustainable growth

Measure 4-2: Strategic Investment

- **In addition to enhancing our in-house production and development capabilities through strategic investments in the Mishima Plant and Clinical Lab, we will continue to introduce new technologies through capital alliances with start-ups and other companies.**

	Mishima Factory	TAUNS Clinicla Lab	Capital Alliance
			ImmuniT Research Inc. GENEX KINS Aillis CRAIF
Investment amount	**approx. 5.1 billion yen** **(approx. 11.7 billion yen cuml.)**	**Approx. 300 million yen**	**Up to 15 billion yen maximum**
Investment effect	• Expansion of production capacity • Improvement of production efficiency and quality stability through FA and in-house production • Introduction of automated warehouses and reduction of logistics costs • BCP • Enhancement of factory tour facilities targeting local elementary and junior high schools	• Expand testing capabilities and capacity by introducing NGS and other cutting-edge testing equipment. Undertake testing service for capital alliance partners such as ImmuniT Research, KINS, and Aillis • Contribute to creation of new products and services through joint research with contracted testing partners	• Strategically invest in potential partners with advanced testing technologies and data utilization platforms. Continue to strengthen TAUNS' technological base.

Measure 4: Strengthening of Management Base



Measure 4-3: Human Capital Investment - Main Initiatives

- **During this period of change, as existing businesses expand and new challenges arise, we will promote human resource development and work environment improvement.**

Invest in “people” as management resource over mid to long term
to support sustainable growth of organization.

Direction of recruitment and training

- Promote HR strategies by combining local business talent with highly specialized professionals
- Support growth from “single talent specialized individuals” to “T-shaped professional capable of working in multiple fields”
- Encourage managers and management candidates to gain experience in other departments to broaden their perspectives and strengthen their management skills

Approach to Work Styles and Systems

- Promote creation of attractive workplaces where diverse human resources, including seniors and women, can play active role
- Promote flexible working styles tailored to individual needs, such as life stage and career aspirations (remote work, flexible hours, etc.)

Adoption of New Technologies

- Strengthen adaptability to new technologies such as AI implementation and operational efficiency improvements
- Strengthen acquisition of specialized human resources in cutting-edge fields (DX, AI, data analysis, new fields)
- Consciously increase opportunities for employees to “experience” new technologies, thereby enhancing sensitivity and affinity in the workplace

Business Performance

- **During the mid-term management plan period, we will aim to establish a new revenue base in new areas in addition to growing existing areas.**
- **We expect full-scale growth in new areas from the fiscal year ending June 30, 2031.**



New areas: New POCT platforms such as D-IA and nodoca (see P9) and new businesses such as testing services at TAUNS Clinical Lab (see P12).

Shareholder Return Information

- **We will introduce a progressive dividend starting at 28 yen during the mid-term management plan period beginning in FY June 2026.**
- **We will conduct share buybacks as necessary, considering the business environment and stock market trends.**

Background to introduction of progressive dividends

- Following its listing on the Tokyo Stock Exchange Standard Market, the company implemented dividends consisting of a dividend payout ratio of 30% plus a commemorative dividend for FY 2024/6 and FY 2025/6.
- Given that our business performance may be affected by the spread of infectious diseases, we have determined that maintaining a dividend policy with a high degree of downward rigidity, even if there are short-term fluctuations in performance, will be in the best interests of our investors. In light of our mid to long-term growth prospects, we will introduce a progressive dividend policy starting at 28 yen per share for FY 2026/6.
- Even with the introduction of this dividend policy, we believe that we will be able to secure the investment resources necessary for our future growth strategy.

(Yen, %)	Interim dividend	Year-end dividend	Annual dividend	Remarks
FY 2024/6	6.00	21.75	27.75	Special dividend of 11.10 yen per share to commemorate listing on the Tokyo Stock Exchange Standard Market
FY 2025/6	6.00	22.00	28.00	Special anniversary dividend of 10.00 yen per share will be paid at the end of the FY to celebrate the 10th anniversary of the Company's establishment.
FY 2026/6 (Forcast)	6.00	22.00	28.00	From FY 2026/6 to FY 2030/6, a progressive dividend will be introduced, starting at 28 yen per share.
until FY 2030/6	-	-	28.00+	same as above

Sustainability Initiatives

Strengthening organization for promoting sustainability

Establishment of Sustainability Committee

- Establish a system for sharing and improving materiality across departments

Redifining and expanding materiality

- Incorporate “promotion of personalized medicine and predictive medicine” into materiality
- Advance research base and establish a sustainable data utilization system
- Promote an ecosystem that continuously advances medical technologies and products

Strategy and tactics development and execution

Designing KGI/KPIs aligned with materiality

- Establish a tracking system that aligns materiality and KPIs in each business area and reflects them in evaluations of departments

Responsibility for sustainable and stable supply

- More efficient supply system and BCP with new factory

Expansion of HR development and training programs

- Support the growth of “T-shaped human resources” who can respond to multiple areas, rather than “human resources specialized in a single area” in order to steadily execute strategies in a changing business environment

Enhancing sustainability through stakeholder feedback

- Medical-related companies, academic institutions, and capital alliance partners with whom we conduct joint research
- Institutional and individual investors
- Customers, suppliers
- External directors and auditors
- Outside experts with specialized knowledge

【Important Notice regarding this Material】

The forward-looking statements contained in this document are based on judgments and assumptions made by the Company as of the date of this document, based on information available to the Company at that time, including industry trends, customer conditions, and other factors. Actual results may differ materially from those described in this document due to uncertainties and changes in internal and external conditions.